Fibroblast Activation Protein Expression in Sarcomas.
Journal
Sarcoma
ISSN: 1357-714X
Titre abrégé: Sarcoma
Pays: Egypt
ID NLM: 9709257
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
09
2022
revised:
03
05
2023
accepted:
23
05
2023
medline:
19
6
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
epublish
Résumé
Fibroblast activation protein alpha (FAP) is highly expressed by cancer-associated fibroblasts in multiple epithelial cancers. The aim of this study was to characterize FAP expression in sarcomas to explore its potential utility as a diagnostic and therapeutic target and prognostic biomarker in sarcomas. Available tissue samples from patients with bone or soft tissue tumors were identified at the University of California, Los Angeles. FAP expression was evaluated via immunohistochemistry (IHC) in tumor samples ( The majority of tumor samples had FAP IHC intensity scores ≥2 and density scores ≥25% for stromal cells (77.7%) and tumor cells (50.7%). All desmoid fibromatosis, myxofibrosarcoma, solitary fibrous tumor, and undifferentiated pleomorphic sarcoma samples had medium or high FAP overall scores. Sarcomas were among cancer types with the highest mean FAP expression by RNA sequencing. There was no significant difference in OS in patients with sarcoma with low versus high FAP expression. The majority of the sarcoma samples showed FAP expression by both stromal and tumor/nonstromal cells. Further investigation of FAP as a potential diagnostic and therapeutic target in sarcomas is warranted.
Identifiants
pubmed: 37333052
doi: 10.1155/2023/2480493
pmc: PMC10275689
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2480493Informations de copyright
Copyright © 2023 Jacquelyn N. Crane et al.
Déclaration de conflit d'intérêts
F.C.E. is on the Scientific Advisory Board of Certis Oncology. T.G.G. has consulting and equity agreements with Auron Therapeutics, Boundless Bio, Coherus BioSciences, and Trethera Corporation. The authors declare that they have no conflicts of interest.
Références
Ann Surg Oncol. 2011 Mar;18(3):720-5
pubmed: 20878245
Int J Cancer. 2016 Feb 15;138(4):1013-23
pubmed: 26334777
Oncogene. 2018 Aug;37(32):4343-4357
pubmed: 29720723
Proc Natl Acad Sci U S A. 1988 May;85(9):3110-4
pubmed: 2896356
Nat Biotechnol. 2017 Apr 11;35(4):314-316
pubmed: 28398314
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Clin Cancer Res. 2018 Aug 15;24(16):3981-3993
pubmed: 29748183
Front Immunol. 2019 Aug 02;10:1835
pubmed: 31428105
J Nucl Med. 2019 Oct;60(10):1421-1429
pubmed: 30850501
Cancer Discov. 2019 Jan;9(1):46-63
pubmed: 30266815
Clin Cancer Res. 2003 May;9(5):1639-47
pubmed: 12738716
Cancer Biol Ther. 2012 Feb 1;13(3):123-9
pubmed: 22236832
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
J Exp Med. 2013 Jun 3;210(6):1125-35
pubmed: 23712432
Nat Rev Drug Discov. 2019 Feb;18(2):99-115
pubmed: 30470818
J Nucl Med. 2022 Jul;63(7):1021-1026
pubmed: 34740953
Cancer Res. 2016 Jul 15;76(14):4124-35
pubmed: 27216177
BMC Cancer. 2012 Dec 22;12:615
pubmed: 23259649
Cancer Immunol Res. 2014 Feb;2(2):154-66
pubmed: 24778279
Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235-9
pubmed: 2402505
J Nucl Med. 2022 Jan;63(1):89-95
pubmed: 33931468
Nat Rev Immunol. 2015 Nov;15(11):669-82
pubmed: 26471778
Mol Ther. 2013 Aug;21(8):1611-20
pubmed: 23732988
Clin Exp Med. 2020 Feb;20(1):121-130
pubmed: 31745677
J Clin Invest. 2006 Jul;116(7):1955-62
pubmed: 16794736
Cancer Cell. 2018 Mar 12;33(3):463-479.e10
pubmed: 29455927
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Clin Transl Immunology. 2020 Oct 14;9(10):e1191
pubmed: 33082953
Cancer Res. 1986 Dec;46(12 Pt 1):6406-12
pubmed: 2877731
Arthritis Res Ther. 2006;8(1):R23
pubmed: 16507127
Clin Cancer Res. 2008 Jul 15;14(14):4584-92
pubmed: 18628473
Oncol Lett. 2014 Mar;7(3):699-704
pubmed: 24520291
J Transl Med. 2013 Aug 12;11:187
pubmed: 23937772
Int J Oncol. 2007 Oct;31(4):785-92
pubmed: 17786309
Int J Dev Biol. 2001 Apr;45(2):445-7
pubmed: 11330865
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Adv Exp Med Biol. 2018;1060:99-114
pubmed: 30155624
Cancer Sci. 2010 Nov;101(11):2325-32
pubmed: 20804499
Nat Rev Clin Oncol. 2021 Dec;18(12):792-804
pubmed: 34489603
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Eur J Cancer. 2020 Mar;127:96-107
pubmed: 32004793
Nat Rev Clin Oncol. 2018 Jun;15(6):366-381
pubmed: 29651130
Science. 2010 Nov 5;330(6005):827-30
pubmed: 21051638
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
J Nucl Med. 2020 Aug;61(8):1171-1177
pubmed: 31836685
Cancer Res. 2004 Apr 15;64(8):2712-6
pubmed: 15087384
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):3011-3013
pubmed: 33728499
Ann Surg. 2000 Mar;231(3):380-6
pubmed: 10714631
PLoS Comput Biol. 2020 Feb 5;16(2):e1007313
pubmed: 32023239
Mod Pathol. 1998 Sep;11(9):855-63
pubmed: 9758365
Immunotargets Ther. 2021 Aug 05;10:313-323
pubmed: 34386436
J Nucl Med. 2019 Mar;60(3):386-392
pubmed: 30072500
Curr Mol Med. 2012 Dec;12(10):1220-43
pubmed: 22834826
J Surg Oncol. 2013 Sep;108(3):157-62
pubmed: 23813624
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
Histopathology. 2009 Oct;55(4):432-40
pubmed: 19817894
Mod Pathol. 2012 Sep;25(9):1298-306
pubmed: 22575866
Br J Haematol. 2008 Sep;142(5):827-30
pubmed: 18510677
Int Rev Cell Mol Biol. 2012;297:83-116
pubmed: 22608558
JCI Insight. 2017 Oct 5;2(19):
pubmed: 28978805
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):3918-3924
pubmed: 34018010
Hum Pathol. 2006 Mar;37(3):352-60
pubmed: 16613331
J Nucl Med. 2022 May;63(5):727-734
pubmed: 34385340
Int J Cancer. 1997 May 2;71(3):383-9
pubmed: 9139873
PLoS One. 2015 Mar 16;10(3):e0116683
pubmed: 25775399
Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2889-2901
pubmed: 35113192